<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142970</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-106</org_study_id>
    <nct_id>NCT04142970</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions</brief_title>
  <official_title>A Clinical Study Comparatively Evaluating the Pharmacokinetics, Pharmacodynamics and Safety of Intravenous Administration of HSK3486 Injectable Emulsion in Patients With Chronic Renal Impairment and Subjects With Normal Renal Functions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Study Comparatively Evaluating the Pharmacokinetics, Pharmacodynamics and Safety&#xD;
      of Intravenous Administration of HSK3486 Injectable Emulsion in Patients with Chronic Renal&#xD;
      Impairment and Subjects with Normal Renal Functions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, non-randomized, parallel-controlled Phase I clinical&#xD;
      study carried out in subjects with varying degrees (mild or moderate) of renal impairment,&#xD;
      and age-, weight-, and gender-matched subjects with normal renal functions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2020</start_date>
  <completion_date type="Actual">August 18, 2020</completion_date>
  <primary_completion_date type="Actual">August 4, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>Cmax（a measure of the body's exposure to HSK3486）will be compared between normal renal function patients and mild or moderate chronic renal impairment patients .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve（AUC）</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>AUC（a measure of the body's exposure to HSK3486）will be compared between normal renal function patients and mild or moderate chronic renal impairment patients .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MOAA/S(modified observer's assessment of alert /sedation)</measure>
    <time_frame>-5 minutes before administration until 1 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral index(BIS)</measure>
    <time_frame>-5 minutes before administration until 1 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>time to peak observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure（systolic, diastolic and mean arterial pressure）</measure>
    <time_frame>from the screening to 3 days post-dose</time_frame>
    <description>safety endpoits</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mild renal impairment (eGFR: 60-89 mL/min/1.73 m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderate renal impairment (eGFR: 30-59 mL/min/1.73 m^2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with normal renal functions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with normal renal functions (eGFR: ≥ 90 mL/min/1.73 m^2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.</description>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_label>Subjects with normal renal functions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Inclusion Criteria (Must Meet All of the Following Criteria):&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females with full capacity for civil conduct, aged ≥ 18 and &lt; 65 years old;&#xD;
&#xD;
          2. Weighing ≥ 45 kg, and with a body mass index (BMI) of ≥ 18 and ≤ 28 kg/ m^2(BMI =&#xD;
             weight (kg)/height2 ( m^2));&#xD;
&#xD;
          3. For matched subjects with normal renal functions: physical examination, laboratory&#xD;
             tests (blood routine, blood biochemistry, urine routine, urinary albumin/creatinine&#xD;
             ratio, creatine kinase (CK) and coagulation function), and 12-lead ECG, etc. should be&#xD;
             normal or abnormal without clinical significance as determined by the investigator;&#xD;
&#xD;
          4. No potential difficult airway (modified Mallampati score of Grade I to II);&#xD;
&#xD;
          5. For matched subjects with normal renal functions: no history of major organ primary&#xD;
             diseases, such as liver, kidneys, digestive tract, blood, and metabolic diseases; no&#xD;
             history of malignant hyperthermia and other genetic conditions; no history of&#xD;
             mental/neurological diseases; no history of epilepsy; no contraindications for deep&#xD;
             sedation/general anesthesia; no clinically significant history of anesthesia&#xD;
             accidents;&#xD;
&#xD;
          6. Subjects must understand the procedures and methods of this study, and be willing to&#xD;
             signing the informed consent form and to complete the trial in strict accordance with&#xD;
             clinical trial protocol;&#xD;
&#xD;
             Patients with Renal Impairment Must Also Meet the Following Criteria:&#xD;
&#xD;
          7. The estimated glomerular filtration rate (eGFR) of the subjects in corresponding&#xD;
             groups meets the criteria for mild to moderate renal impairment in the staging of&#xD;
             renal functions, i.e., mild renal impairment: 60-89 mL/min/1.73 m^2; moderate renal&#xD;
             impairment: 30-59 mL/min/1.73 m^2; subjects with normal renal functions: ≥ 90&#xD;
             mL/min/1.73 m^2;&#xD;
&#xD;
          8. For subjects with renal impairment, their laboratory test results (coagulation&#xD;
             function, blood routine, urinary albumin/creatinine ratio, creatine kinase (CK), blood&#xD;
             biochemistry, and urine routine) should be judged by the investigators as clinically&#xD;
             stable and consistent with the severity of their renal impairment. In addition, their&#xD;
             albumin should be &gt; 35 g/L and hemoglobin should be &gt; 110 g/L;&#xD;
&#xD;
        Exclusion Criteria( those who meet any one of the followings are ineligible):&#xD;
&#xD;
          1. Known sensitivity to excipients in HSK3486 injectable emulsion (soybean oil, glycerin,&#xD;
             triglyceride, egg lecithin, sodium oleate and sodium hydroxide); history of drug&#xD;
             allergies (including other anesthetics);&#xD;
&#xD;
          2. Received any one of the following medications or treatments prior to&#xD;
             screening/enrollment:&#xD;
&#xD;
             History of drug abuse or any signs of long-term use of benzodiazepines (such as&#xD;
             insomnia, anxiety, spasms) within 3 months prior to screening; Participated in&#xD;
             clinical trials involving any medications or medical devices within 3 months prior to&#xD;
             screening, or subjects who have participated in 3 or more drug clinical trials within&#xD;
             the past year; Serious infection, trauma, or major surgery within 4 weeks before&#xD;
             screening; or acute disease with clinical significance (determined by the&#xD;
             investigators) within 2 weeks before screening, including GI diseases or infections&#xD;
             (such as respiratory tract or CNS infections); In receipt of propofol, other&#xD;
             sedatives/anesthetics and/or opioid analgesics or compounds containing analgesics&#xD;
             within 72 hrs prior to baseline; Used potent inhibitors of CYP enzyme within 7 days&#xD;
             prior to enrollment, or used moderate/low potency inhibitors of CYP enzyme within 3&#xD;
             days prior to enrollment;&#xD;
&#xD;
          3. History or evidence of any one of the following diseases prior to&#xD;
             screening/enrollment:&#xD;
&#xD;
             History of cardiovascular diseases such as: uncontrolled hypertension [SBP ≥ 170 mmHg&#xD;
             and/or DBP ≥ 105 without antihypertensive treatment, or SBP &gt; 160 mmHg and/or DBP &gt;&#xD;
             100 mmHg despite antihypertensive treatment], postural hypotension, severe arrhythmia,&#xD;
             heart failure, Adams-Stokes syndrome, unstable angina, myocardial infarction within 6&#xD;
             months before screening, history of tachycardia/bradycardia requiring medication,&#xD;
             II-III degree atrioventricular block (excluding patients with pacemakers) or QTcF&#xD;
             interval ≥ 450 ms (Fridericia's correction formula); Respiratory insufficiency,&#xD;
             history of obstructive pulmonary disease, history of asthma, sleep apnea; history of&#xD;
             failed tracheal intubation; history of bronchospasm requiring treatment within 3&#xD;
             months prior to screening; acute respiratory infection, and with obvious symptoms such&#xD;
             as fever, wheezing, nasal congestion or cough within 1 week prior to baseline; History&#xD;
             of gastrointestinal diseases: History of gastrointestinal retention, moderate and&#xD;
             above active bleeding (GUSTO bleeding classification), gastroesophageal reflux that&#xD;
             may lead to aspiration; [Note: GUSTO bleeding classification is: heavy or&#xD;
             life-threatening bleeding (intracranial hemorrhage or bleeding that causes hemodynamic&#xD;
             compromise and requires intervention), moderate bleeding (requires blood transfusion&#xD;
             but does not cause hemodynamic compromise), minor bleeding (does not meet the criteria&#xD;
             for either severe or moderate bleeding)]; History of cerebrovascular diseases: history&#xD;
             of craniocerebral injury, possible convulsions, intracranial hypertension, cerebral&#xD;
             aneurysm, or cerebrovascular accident; History of mental illness: schizophrenia,&#xD;
             mania, chronic use of antipsychotics, or cognitive impairment;&#xD;
&#xD;
          4. Positive test for either HBsAg, HCV, HIV, or syphilis;&#xD;
&#xD;
          5. History of alcohol abuse within 3 months prior to screening, alcohol abuse defined as&#xD;
             average of &gt; 2 units of alcohol per day (1 unit = 360 mL beer or 45 mL liquor with 40%&#xD;
             alcohol or 150 mL wine), or positive alcohol breath test results at baseline;&#xD;
&#xD;
          6. Smoke more than 5 cigarettes per day and a total of more than 60 cigarettes within 3&#xD;
             months prior to screening;&#xD;
&#xD;
          7. Blood donation or blood loss ≥ 200 mL within 30 days prior to screening; plasma&#xD;
             donation or plasma exchange within 7 days prior to screening;&#xD;
&#xD;
          8. Subjects who have consumed any beverages or foods containing alcohol, grapefruit juice&#xD;
             or methylxanthine (such as coffee, tea, cola, chocolate, and functional drinks),&#xD;
             participated in strenuous physical activities and other factors that may affect drug&#xD;
             absorption, distribution, metabolism, and excretion within 2 days prior to baseline;&#xD;
             subjects who are unable to fast for 8 hrs before dose administration;&#xD;
&#xD;
          9. Subjects expected to have surgery or hospitalization during the trial;&#xD;
&#xD;
         10. Subjects unsuitable for arterial blood collection, such as subjects who have positive&#xD;
             Allen's test results;&#xD;
&#xD;
         11. Other than the disease diagnosed as renal impairment, patients with acute illnesses in&#xD;
             any other organ, as well as those with chronic conditions that may affect the in vivo&#xD;
             process of the investigational drug (e.g., chronic hepatitis, hepatic insufficiency,&#xD;
             etc.);&#xD;
&#xD;
         12. Patients with autoimmune nephropathy, obstructive nephropathy, history of kidney&#xD;
             transplantation, and an ongoing dialysis treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>He Nan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild renal impairment</keyword>
  <keyword>Moderate renal impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

